 |
|
 |
|
|
|
|
 |
 |
 |
|
Connetics Corporation ("CNCT") is an emerging pharmaceutical company focused on the development and commercialization of products in niche dermatology and rheumatology markets. CNCT’s is executing a reduced-risk, three-part strategy: (1) to in-license and acquire FDA-approved products, or late-stage products in development, (2) to develop and market these novel products through its targeted sales force, focused on the dermatology and rheumatology markets, and (3) to engage in corporate partnerships to market products outside the U.S. that should generate royalty streams to CNCT. CNCT currently markets three products (Luxiq(TM) Ridaura® and ACTIMMUNE®) through a specialized sales force that calls on high-prescribing dermatologists and rheumatologists in the U.S. CNCT also has two promising products (OLUXÔ and ConXnÔ ) in late-stage clinical development.
SMALLCAPS
RESEARCH
Initial Opinion -- HTML (07/06/99)